IL111843A - Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparation - Google Patents
Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparationInfo
- Publication number
- IL111843A IL111843A IL11184394A IL11184394A IL111843A IL 111843 A IL111843 A IL 111843A IL 11184394 A IL11184394 A IL 11184394A IL 11184394 A IL11184394 A IL 11184394A IL 111843 A IL111843 A IL 111843A
- Authority
- IL
- Israel
- Prior art keywords
- phenylprop
- crystalline
- processes
- preparation
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/164,074 US5434171A (en) | 1993-12-08 | 1993-12-08 | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL111843A0 IL111843A0 (en) | 1995-03-15 |
| IL111843A true IL111843A (en) | 2000-02-29 |
Family
ID=22592858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11184394A IL111843A (en) | 1993-12-08 | 1994-12-01 | Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparation |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5434171A (es) |
| EP (3) | EP0657428B1 (es) |
| JP (2) | JP3834075B2 (es) |
| KR (1) | KR100356239B1 (es) |
| CN (2) | CN1057294C (es) |
| AT (1) | ATE200279T1 (es) |
| AU (1) | AU681198B2 (es) |
| BR (1) | BR9404842A (es) |
| CA (1) | CA2137221C (es) |
| CO (1) | CO4290427A1 (es) |
| CZ (1) | CZ290559B6 (es) |
| DE (1) | DE69427017T2 (es) |
| DK (1) | DK0657428T3 (es) |
| ES (1) | ES2155844T3 (es) |
| FI (2) | FI106455B (es) |
| GR (1) | GR3036136T3 (es) |
| HK (1) | HK1013826A1 (es) |
| HU (1) | HUT71489A (es) |
| IL (1) | IL111843A (es) |
| MY (1) | MY121543A (es) |
| NO (1) | NO302884B1 (es) |
| NZ (1) | NZ270039A (es) |
| PE (1) | PE41495A1 (es) |
| PL (1) | PL181734B1 (es) |
| PT (1) | PT657428E (es) |
| RU (1) | RU2145958C1 (es) |
| SI (1) | SI0657428T1 (es) |
| TW (1) | TW290540B (es) |
| UA (1) | UA52577C2 (es) |
| YU (2) | YU49312B (es) |
| ZA (1) | ZA949584B (es) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722497B1 (fr) * | 1994-07-13 | 1996-08-14 | Synthelabo | Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique |
| HN1999000149A (es) * | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
| GB9912413D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912417D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912411D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912410D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912416D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9912415D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
| AU2002314967B2 (en) * | 2001-06-05 | 2007-09-20 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
| US20030068829A1 (en) * | 2001-06-25 | 2003-04-10 | Symyx Technologies, Inc. | High throughput crystallographic screening of materials |
| MXPA04003597A (es) | 2001-10-18 | 2004-07-30 | Nektar Therapeutics Al Corp | Conjugados polimericos de antagonistas opiaceos. |
| US6794510B2 (en) * | 2002-08-08 | 2004-09-21 | Adolor Corporation | Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto |
| US7381721B2 (en) * | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| DK2368553T3 (en) | 2003-04-08 | 2015-02-09 | Progenics Pharm Inc | Pharmaceutical preparation comprising methylnaltrexone |
| WO2004091622A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| US6992090B2 (en) * | 2003-06-16 | 2006-01-31 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| FR2861304B1 (fr) * | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | Modulateurs des canaux cftr |
| US20050148630A1 (en) * | 2003-12-02 | 2005-07-07 | Carpenter Randall L. | Methods of preventing and treating non-opioid induced gastrointestinal dysfunction |
| US8946262B2 (en) * | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
| PL1694363T3 (pl) * | 2003-12-16 | 2014-07-31 | Nektar Therapeutics | Monodyspersyjne kompozycje PEGylowanego naloksolu |
| US20060182692A1 (en) * | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
| US7087749B2 (en) * | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| US20050240177A1 (en) * | 2004-04-26 | 2005-10-27 | Packaging Service Corporation Of Kentucky | Electrosurgical forceps |
| US7700626B2 (en) * | 2004-06-04 | 2010-04-20 | Adolor Corporation | Compositions containing opioid antagonists |
| US8039456B2 (en) | 2004-08-12 | 2011-10-18 | Helsinn Therapeutics (U.S.), Inc. | Method of stimulating the motility of the gastrointestinal system using ipamorelin |
| US20070191283A1 (en) * | 2004-08-12 | 2007-08-16 | Rejuvenon Corporation | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |
| US20060063792A1 (en) * | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| US20060211733A1 (en) * | 2005-03-04 | 2006-09-21 | Adolor Corporation | Methods of preventing and treating opioid bowel dysfunction |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| CN101171010B (zh) * | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| CA2616918A1 (en) * | 2005-07-01 | 2007-01-11 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| US7914776B2 (en) * | 2005-10-07 | 2011-03-29 | Adolor Corporation | Solid dispersions of opioid antagonists |
| US20070092576A1 (en) * | 2005-10-20 | 2007-04-26 | Adolor Corporation | Compositions containing opioid antagonists |
| US7538110B2 (en) * | 2005-10-27 | 2009-05-26 | Adolor Corporation | Opioid antagonists |
| CN100383121C (zh) * | 2006-03-07 | 2008-04-23 | 天津泰普药品科技发展有限公司 | 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺 |
| JP5176188B2 (ja) | 2006-04-21 | 2013-04-03 | ディーエスエム アイピー アセッツ ビー．ブイ． | オピオイド受容体拮抗薬の使用 |
| WO2008064353A2 (en) * | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | 7,8-saturated-4,5-epoxy-morphinanium analogs |
| EP2134718A2 (en) | 2007-03-29 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
| PL2137191T3 (pl) | 2007-03-29 | 2016-12-30 | Antagoniści obwodowego receptora opioidowego i ich zastosowania | |
| PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
| AU2008349873B2 (en) | 2008-02-06 | 2014-02-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| JP5588983B2 (ja) | 2008-08-11 | 2014-09-10 | ウェルズ ファーゴ バンク ナショナル アソシエイション | マルチアームポリマーアルカノエートコンジュゲート |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| CN101429154B (zh) * | 2008-11-14 | 2011-01-05 | 天津泰普药品科技发展有限公司 | 无水阿维莫泮及其药物组合物 |
| US20100311782A1 (en) | 2009-06-08 | 2010-12-09 | Adolor Corporation | Substituted piperidinylpropanoic acid compounds and methods of their use |
| HUE043963T2 (hu) | 2009-12-04 | 2019-09-30 | Alkermes Pharma Ireland Ltd | Morfinán származékok gyógyszer-túladagolás kezelésére |
| WO2011161646A2 (en) | 2010-06-25 | 2011-12-29 | Ranbaxy Laboratories Limited | Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| US20140088021A1 (en) | 2011-05-27 | 2014-03-27 | Nektar Therapeutics | Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds |
| CN103360302B (zh) * | 2012-03-29 | 2015-08-26 | 北大方正集团有限公司 | 阿维莫泮的纯化方法 |
| US10314839B2 (en) | 2014-10-20 | 2019-06-11 | Elysium Therapeutics, Inc. | Diversion-resistant opioid formulations |
| GB2556817B (en) | 2015-10-01 | 2019-11-06 | Elysium Therapeutics Inc | Polysubunit opioid prodrugs resistant to overdose and abuse |
| US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
| CA3056239C (en) | 2017-03-17 | 2023-09-12 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5136040A (en) * | 1991-02-26 | 1992-08-04 | Eli Lilly And Company | Preparation of substituted tetrahydropyridines |
| US5250542A (en) * | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
| NZ242117A (en) * | 1991-03-29 | 1994-11-25 | Lilly Co Eli | 4-phenylpiperidine derivatives and medicaments containing them |
-
1993
- 1993-12-08 US US08/164,074 patent/US5434171A/en not_active Expired - Lifetime
-
1994
- 1994-12-01 TW TW083111189A patent/TW290540B/zh not_active IP Right Cessation
- 1994-12-01 ZA ZA949584A patent/ZA949584B/xx unknown
- 1994-12-01 PE PE1994256135A patent/PE41495A1/es not_active Application Discontinuation
- 1994-12-01 NZ NZ270039A patent/NZ270039A/en not_active IP Right Cessation
- 1994-12-01 AU AU79170/94A patent/AU681198B2/en not_active Ceased
- 1994-12-01 CZ CZ19942992A patent/CZ290559B6/cs not_active IP Right Cessation
- 1994-12-01 PL PL94306068A patent/PL181734B1/pl not_active IP Right Cessation
- 1994-12-01 IL IL11184394A patent/IL111843A/xx not_active IP Right Cessation
- 1994-12-01 JP JP29835694A patent/JP3834075B2/ja not_active Expired - Fee Related
- 1994-12-02 DK DK94308951T patent/DK0657428T3/da active
- 1994-12-02 RU RU94042903A patent/RU2145958C1/ru not_active IP Right Cessation
- 1994-12-02 DE DE69427017T patent/DE69427017T2/de not_active Expired - Lifetime
- 1994-12-02 EP EP94308951A patent/EP0657428B1/en not_active Expired - Lifetime
- 1994-12-02 CA CA2137221A patent/CA2137221C/en not_active Expired - Fee Related
- 1994-12-02 FI FI945703A patent/FI106455B/fi not_active IP Right Cessation
- 1994-12-02 SI SI9430367T patent/SI0657428T1/xx unknown
- 1994-12-02 UA UA94129124A patent/UA52577C2/uk unknown
- 1994-12-02 CO CO94055028A patent/CO4290427A1/es unknown
- 1994-12-02 PT PT94308951T patent/PT657428E/pt unknown
- 1994-12-02 HU HU9403466A patent/HUT71489A/hu unknown
- 1994-12-02 YU YU70294A patent/YU49312B/sh unknown
- 1994-12-02 YU YU82304A patent/YU82304A/sh unknown
- 1994-12-02 BR BR9404842A patent/BR9404842A/pt not_active Application Discontinuation
- 1994-12-02 EP EP05077072A patent/EP1607387A3/en not_active Withdrawn
- 1994-12-02 ES ES94308951T patent/ES2155844T3/es not_active Expired - Lifetime
- 1994-12-02 EP EP99203390A patent/EP0984004A3/en not_active Withdrawn
- 1994-12-02 AT AT94308951T patent/ATE200279T1/de not_active IP Right Cessation
- 1994-12-02 NO NO944644A patent/NO302884B1/no not_active IP Right Cessation
- 1994-12-03 CN CN94119376A patent/CN1057294C/zh not_active Expired - Fee Related
- 1994-12-05 KR KR1019940032794A patent/KR100356239B1/ko not_active IP Right Cessation
- 1994-12-05 MY MYPI94003238A patent/MY121543A/en unknown
-
1998
- 1998-12-03 CN CN98123069A patent/CN1121387C/zh not_active Expired - Fee Related
- 1998-12-23 HK HK98115194A patent/HK1013826A1/xx not_active IP Right Cessation
-
2000
- 2000-02-17 FI FI20000353A patent/FI106860B/fi not_active IP Right Cessation
-
2001
- 2001-06-27 GR GR20010400990T patent/GR3036136T3/el not_active IP Right Cessation
-
2005
- 2005-10-18 JP JP2005303195A patent/JP2006070042A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL111843A (en) | Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparation | |
| UA34428C2 (uk) | Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки | |
| HUT52070A (en) | Herbicide compositions containing pyrimidinyl-benzoic acid derivatives as active components, and process for producing the active components | |
| AU1331588A (en) | Method for treatment of alcohol abuse | |
| CA2263563A1 (en) | Cyclopentenones, process for preparing the same, and the use thereof | |
| PL295331A1 (en) | Method of obtaining novel derivatives of quinolonocarboxylic acid | |
| AU661591B2 (en) | 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds | |
| HUT47793A (en) | Herbicide compositions containing 2,6-substituted-pyridine-carboxylic acid derivatives as active components and process for producing the active components | |
| CS235488A2 (en) | Method of new dihydropyridinamides production | |
| HUT41984A (en) | Process for producing pharmaceutical compositions containing 9,10-dihydro-ergot-alkaloides | |
| EP0521393A3 (en) | Diclofenac salt, a method for the preparation thereof and pharmaceutical compositions containing it | |
| IL81831A0 (en) | Method and compositions for controlling weeds containing 1-methyl-1h-imidazole-5-carboxylic acid derivatives,certain such novel compounds and their preparation | |
| HUT53643A (en) | Process for producing substituted azetidinye-pyridon-carboxylic acid derivatives and pharmaceutical compositions containing them | |
| HUT47792A (en) | Herbicide compositions containing 2,6-substituted-pyridine-carboxylic acid derivatives as active components and process for producing the active components | |
| SG52396A1 (en) | Process for preparing purified 2,6-naphtalenedicorboxylic acid | |
| KR960015807B1 (en) | Process for the preparation of purified bis(2-hydrozyethyl) ester of 2,60naphthalenedi carboxylic acid | |
| NZ332245A (en) | Substituted benzo-oxazolol carboxylic acid derivatives, process for their production and medicaments containing them | |
| HUT48898A (en) | Process for producing intermediate compounds for producing herbicide compositions containing amino-methylene-phosphonic acid derivatives | |
| HU9302546D0 (en) | Heteroarenyl-piperazine derivatives, method for producing them and medical preparatives containing said compounds | |
| HUT48461A (en) | Process for producing pharmaceutical compositions containing 1,4-dihydropyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| FF | Patent granted | ||
| KB | Patent renewed | ||
| EXP | Patent expired |